Hoermann R, Broecker M, Grossmann M, Mann K, Derwahl M
Medical Department II, Klinikum Grosshadern, University of Munich, Germany.
J Clin Endocrinol Metab. 1994 Apr;78(4):933-8. doi: 10.1210/jcem.78.4.8157724.
hCG is a putative thyroid stimulator. The present studies were undertaken to examine its interaction and that of its desialylated variant asialo-hCG with recombinant human TSH (hTSH) receptor (hTSHr). To this end, we transfected a human thyroid carcinoma cell line (HTC) lacking endogenous TSHr with the full-length cDNA of the hTSHr. Unlike the wild type, the transfected cells, termed HTC-TSHr cells, were able to bind bovine TSH (bTSH) with high affinity and increase cAMP production in response to bTSH stimulation. Of the hCG forms, intact hCG displayed a weak activity to inhibit [125I] bTSH binding to HTC-TSHr cells, with 100 mg/L (2.6 x 10(-6) mol/L) producing maximally a 20% inhibition, whereas asialo-hCG achieved half-maximum binding inhibition at a concentration of 8 mg/L (2.3 x 10(-7) mol/L). The inhibitory constant (Ki) of asialo-hCG for recombinant hTSHr was calculated from saturation experiments in the presence of variable doses of bTSH and a fixed concentration of asialo-hCG to be approximately 8 x 10(-8) mol/L. The interaction of asialo-hCG with TSHr was further assessed by studies of the direct binding of the radioactively labeled hormone to both HTC and HTC-TSHr cells. [125I]Asialo-hCG binding to HTC-TSHr cells was 4.7%, compared to 1.5% in the wild-type cells lacking TSHr and was displaceable by bTSH (0.1-100 IU/L), indicating specific binding of the tracer to TSHr. Functionally, hCG (up to 100 mg/L; 2.6 x 10(-6) mol/L) proved unable to evoke any significant cAMP response over basal values in HTC-TSHr cells, as did asialo-hCG. Asialo-hCG, but not hCG, inhibited bTSH-stimulated adenylate cyclase activity in the cells in a dose-dependent manner. In conclusion, the present data show that intact hCG binds only weakly to HTC-TSHr cells and produces no significant cAMP stimulation, which is at variance with data obtained in FRTL-5 and Chinese hamster ovary-TSHr cells, but in good accord with previous findings in human thyroid membranes. Asialo-hCG, on the other hand, strongly binds to recombinant TSHr and inhibits the cAMP response to bTSH in HTC-TSHr cells, indicating that the desialylated hCG variant directly interacts with the receptor and truly is an antagonist of the hTSHr.
人绒毛膜促性腺激素(hCG)是一种假定的甲状腺刺激物。本研究旨在检测其与重组人促甲状腺激素(hTSH)受体(hTSHr)的相互作用,以及其去唾液酸化变体脱唾液酸hCG与该受体的相互作用。为此,我们用hTSHr的全长cDNA转染了一种缺乏内源性TSHr的人甲状腺癌细胞系(HTC)。与野生型细胞不同,转染后的细胞(称为HTC-TSHr细胞)能够以高亲和力结合牛促甲状腺激素(bTSH),并在bTSH刺激下增加环磷酸腺苷(cAMP)的产生。在hCG的各种形式中,完整的hCG对抑制[125I]bTSH与HTC-TSHr细胞的结合表现出较弱的活性,100 mg/L(2.6×10⁻⁶ mol/L)时最大抑制率为20%,而脱唾液酸hCG在浓度为8 mg/L(2.3×10⁻⁷ mol/L)时达到半数最大结合抑制。通过在不同剂量bTSH和固定浓度脱唾液酸hCG存在下的饱和实验计算得出,脱唾液酸hCG对重组hTSHr的抑制常数(Ki)约为8×10⁻⁸ mol/L。通过研究放射性标记激素与HTC和HTC-TSHr细胞的直接结合,进一步评估了脱唾液酸hCG与TSHr的相互作用。[125I]脱唾液酸hCG与HTC-TSHr细胞的结合率为4.7%,而在缺乏TSHr的野生型细胞中为1.5%,且可被bTSH(0.1 - 100 IU/L)取代,表明示踪剂与TSHr存在特异性结合。在功能上,hCG(高达100 mg/L;2.6×10⁻⁶ mol/L)在HTC-TSHr细胞中未能引起任何超过基础值的显著cAMP反应,脱唾液酸hCG也是如此。脱唾液酸hCG而非hCG以剂量依赖的方式抑制细胞中bTSH刺激的腺苷酸环化酶活性。总之,目前的数据表明,完整的hCG仅与HTC-TSHr细胞弱结合,且不产生显著的cAMP刺激,这与在FRTL-5和中国仓鼠卵巢-TSHr细胞中获得的数据不同,但与先前在人甲状腺膜中的发现一致。另一方面,脱唾液酸hCG与重组TSHr强烈结合,并抑制HTC-TSHr细胞中对bTSH的cAMP反应,表明去唾液酸化的hCG变体直接与受体相互作用,实际上是hTSHr的拮抗剂。